Review
Open access
Sep 2026
Antibody-drug conjugates in treatment-resistant hepatocellular carcinoma: mechanistic insights, translational barriers, and a blueprint for salvage-line precision oncology.
Despite advances in immune checkpoint inhibitor (ICI)-based therapy, hepatocellular carcinoma (HCC) frequently develops treatment resistance, creating a need for mechanistically distinct therapies. Antibody-drug conjugates (ADCs) combine tumor-directed recognition with intracellular payload delivery, but their developm...
Wen-Xun Cai, Suo-Yi Dai, Yu-Hang Chen et al.
· Biochimica et biophysica act... · 0 citations